Inflammasomes and Cardiovascular Disease: Linking Inflammation to Cardiovascular Pathophysiology

Scandinavian Journal of Immunology, Год журнала: 2025, Номер 101(4)

Опубликована: Апрель 1, 2025

Cardiovascular diseases (CVDs) remain a leading cause of global mortality, driven by risk factors such as dyslipidemia, hypertension and diabetes. Recent research has highlighted the critical role inflammasomes, particularly NLRP3 inflammasome, in pathogenesis various CVDs, including hypertension, atherosclerosis, myocardial infarction heart failure. Inflammasomes are intracellular protein complexes that activate inflammatory responses through production pro-inflammatory cytokines IL-1β IL-18, contributing to endothelial dysfunction, plaque formation injury. This review provides comprehensive overview structure, activation mechanisms pathways with focus on their involvement cardiovascular pathology. Key include ion fluxes (K+ efflux Ca2+ signalling), endoplasmic reticulum (ER) stress, mitochondrial dysfunction lysosomal destabilisation. The also explores therapeutic potential targeting inflammasomes mitigate inflammation improve outcomes CVDs. Emerging strategies small-molecule inhibitors, biologics RNA-based therapeutics, particular emphasis inhibition. Additionally, integration artificial intelligence (AI) offers promising avenues for identifying novel biomarkers, predicting disease developing personalised treatment strategies. Future directions should understanding interactions between other immune components, well genetic regulators, uncover new targets. By elucidating complex this underscores innovative therapies address inflammation-driven pathology, ultimately improving patient outcomes.

Язык: Английский

Targeting p53-p21 signaling to enhance mesenchymal stem cell regenerative potential

Regenerative Therapy, Год журнала: 2025, Номер 29, С. 352 - 363

Опубликована: Апрель 8, 2025

Язык: Английский